jussi t





UHN Fellow

First Name

jussi t



Institutional Affiliations



Project Title

Quality Improvement of Lab Management at the Latner Thoracic Research Program: Scientific direction of research streams

Project Description

This project aims to first identify and assess issues voiced out in large labs regarding project completion and workflows, as well as to identify and assess main, current methods being used to manage projects and workflow in different industries as well as the issues voiced out in labs. From these assessments, one or two methods for project management and quality improvement of workflows will be selected, potentially modified, and potentially applied (with pilot testing) to the Latner lab’s situation. One of these outcomes will be to build an editable map of the research program (see Appendix I). In its entirety, the project aims to improve the managements (ex. through tools, logistic-improvement, policies, guidelines, etc) of the research laboratory to enhance the research output and educational value of the laboratory.



Original articles in peer-reviewed journals: (2013 impact factors, 2013 ISI ranking and number of citations as of January 2015)1.Tikkanen J, Lemstrom K, Halme M, Pakkala S, Taskinen E, Koskinen P. Cytological monitoring of peripheral blood, bronchoalveolar lavage fluid, and transbronchial biopsy specimens during acute rejection and cytomegalovirus infection in lung and heart–lung allograft recipients. Clin Transplant 2001;15(2):77-88. (IF 1.486: ISI 18; citations: 14)2.Tikkanen JM, Kallio EA, Bruggeman CA, Koskinen PK, Lemstrom KB. Prevention of cytomegalovirus infection-enhanced experimental obliterative bronchiolitis by antiviral prophylaxis or immunosuppression in rat tracheal allografts. Am J Respir Crit Care Med 2001; 164(4): 672-9. (IF: 11.986; ISI 1; citations: 30)3.Tikkanen JM, Lemstrom KB, Koskinen PK. Blockade of CD28/B7-2 costimulation inhibits experimental obliterative bronchiolitis in rat tracheal allografts: suppression of helper T cell type1-dominated immune response. Am J Respir Crit Care Med 2002; 165(5): 724-9. (IF: 11.986; ISI 1; citations: 30)4.Lemström KB, Krebs R, Nykänen AI, Tikkanen JM, Sihvola RK, Aaltola EM, et al. Vascular endothelial growth factor enhances cardiac allograft arteriosclerosis. Circulation 2002; 105(21): 2524-30. (IF: 14.948; ISI 1; citations: 79)5.Sihvola RK, Tikkanen JM, Krebs R, Aaltola EM, Buchdunger E, Laitinen O, et al. Platelet-derived growth factor receptor inhibition reduces allograft arteriosclerosis of heart and aorta in cholesterol-fed rabbits. Transplantation. 2003; 75(3): 334-9. (IF: 3.535; ISI 6; citations: 16)6.Tikkanen JM, Lemstrom KB, Bruggeman CA, Koskinen PK. Platelet-derived Growth Factor Regulates Cytomegalovirus Infection-Enhanced Obliterative Bronchiolitis in Rat Tracheal Allografts. Transplantation 2004; 77: 655-668. (IF:3.535; ISI 6; citations: 6)7.Tikkanen JM, Koskinen PK, Lemstrom KB. Role of endogenous endothelin-1 in transplant obliterative airway disease in the rat. Am J Transplant 2004; 4: 713-720. (IF: 6.190; ISI 1; citations: 13)8.Krebs R, Tikkanen JM, Nykänen AI, Koskinen PK, Lemström KB. Dual role of VEGF in obliterative bronchiolitis in rat tracheal allografts. Am J Resp Crit Care Med 2005; 171: 1421-1429. (IF: 11.986; ISI 1; citations: 23)9. Nykänen AI, Krebs R, Tikkanen JM, Raisky O, Sihvola R, Wood J, Koskinen PK, Lemström KB. Combined vascular endothelial growth factor and platelet-derived growth factor inhibition in rat cardiac allografts: beneficial effects on inflammation and smooth muscle cell proliferation. Transplantation 2005; 79: 182-189. (IF: 3.535; ISI 6; citations: 21)10.Sihvola RK, Koskinen PK, Pulkkinen VP, Tikkanen JM, Lemström KB. Inhibition of Tumor Necrosis Factor- Attenuates Myocardial Remodeling in Rat Cardiac Allografts. J Heart Lung Transplant 2006; 25(5):569-78. (IF: 5.611; ISI 2; citations: 2)11.Tikkanen JM, Hollmén M, Nykänen AI, Wood J, Koskinen PK, Lemström KB. Role of platelet-derived growth factor and vascular endothelial growth factor in obliterative airway disease. Am J Respir Crit Care Med 2006; 174:1145-1152. (IF: 11.986; ISI 1; citations: 17)12.Raisky O, Nykänen AI, Krebs R, Hollmén M, Keränen MA, Tikkanen JM, Sihvola R, Alhonen L, Salven P, Wu Y, Hicklin DJ, Alitalo K, Koskinen PK, Lemström KB. VEGFR-1 and VEGFR-2 regulate inflammation, myocardial angiogenesis, and arteriosclerosis in chronically rejecting cardiac allografts. Arterioscler Thromb Vasc Biol 2007;4:819-825. (IF:5.533; ISI 8; citations: 13)13.Hollmén M, Tikkanen JM, Nykänen AI, Koskinen PK, Lemström KB. Tacrolimus treatment effectively inhibits progression of obliterative airway disease even at later stages of disease development. J Heart Lung Transplant. 2008 Aug;27(8):856-64. (IF: 5.611; ISI 2; citations: 9)14.Jokinen JJ, Tikkanen J, Kukkonen S, Hämmäinen P, Lommi J, Sipponen J, Lemström KB. Natural course and risk factors for impaired renal function during the first year after heart transplantation. J Heart Lung Transplant. 2010 Jun;29(6):633-40. (IF: 5.611; ISI 2; citations: 9)15.Ropponen JO, Syrjälä SO, Krebs R, Nykänen A, Tikkanen JM, Lemström KB. Innate and adaptive immune responses in obliterative airway disease in rat tracheal allografts. J Heart Lung Transplant 2011;30(6):707-716. (IF: 5.611; ISI 2; citations: 5)16.Tuuminen R, Syrjälä S, Krebs R, Keränen MA, Koli K, Abo-Ramadan U, Neuvonen PJ, Tikkanen JM, Nykänen AI, Lemström KB. Donor simvastatin treatment abolishes rat cardiac allograft ischemia/reperfusion injury and chronic rejection through microvascular protection. Circulation 2011;124(10):1138-50. (IF: 14.948; ISI 1; citations: 8).17.Ropponen JO, Syrjälä SO, Hollmén M, Tuuminen R, Krebs R, Keränen MA, Vaali K, Nykänen AI, Lemström KB, Tikkanen JM. The effect of simvastatin on development of obliterative bronchiolitis: an experimental study. J Heart Lung Transplant 2012;31:194-203. (IF: 5.611; ISI 2; citations: 1)18.Krebs R, Tikkanen JM, Ropponen JO, Jeltsch M, Jokinen JJ, Ylä-Herttuala S, Nykänen AI, Lemström KB. Critical role of VEGF-C/VEGFR-3 signaling in innate and adaptive immune responses in experimental obliterative bronchiolitis. Am J Pathol. 2012 Nov;181(5):1607-20. (IF: 4.682; ISI 8; citations 5)19.Leppäranta O, Tikkanen JM, Bespalov MM, Koli K, Myllärniemi M. The BMP-inducer tilorone identified by high-throughput screening is antifibrotic in vivo. Am J Respir Cell Mol Biol. 2013;48(4): 448-55 (IF:4.109; ISI 7; citations: 4)20.Tikkanen JM, Cypel M, Machuca TM, Azad S, Binnie M, Chow CW, Chaparro C, Hutcheon M, Yasufuku K, de Perrot M, Pierre AF, Waddell TK, Keshavjee S, Singer LG. Functional outcomes and quality of life after normothermic ex vivo lung perfusion lung transplantation. J Heart Lung Transplant 2014 (in press) (IF: 5.611; ISI 2)21.Myllarniemi M, Tikkanen J, Hulmi JJ, Pasternack A, Sutinen E, Rönty M, Leppäranta O, Ma H, Ritvos O, Koli K. Upregulation of activin-B and follistatin in pulmonary fibrosis – A translational study using human biopsies and a specific inhibitor in mouse fibrosis models. BMC Pulmonary Medicine 2014 (in press) (IF: 2.489; ISI 28).22.Machuca T, Mercier O, Collaud S, Tikkanen JM, Krueger T, Yeung J, Chen M, Azad S, Singer L, Yasufuku K, de Perrot M, Pierre AF, Waddell T, Keshavjee S, Cypel M. Lung Transplantation with Donation after Circulatory Determination of Death Donors and the Impact of Ex vivo Lung Perfusion. Am J Transplant 2014 (in press) (IF 6.190; ISI 1).Abstracts in peer-reviewed journals1.Cytomegalovirus infection accelerates experimental obliterative bronchiolitis via platelet-derived growth factor upregulation. Koskinen P, Kallio E, Tikkanen J, Bruggeman C, Häyry P, Lemström K. Transplant Proc. 1997;29(1-2):798.2.CMV infection and allograft rejection. Häyry P, Lemström K, von Willebrand E, Tikkanen J, Koskinen P. Transplant Proc. 1998;30(3):916-7.3.Detailed analysis of cell profiles in peripheral blood, bronchoalveolar lavage fluid, and transbronchial biopsy specimens during acute rejection and CMV infection in lung and heart-lung allograft recipients. Tikkanen J, Lemström K, Halme M, Pakkala S, Taskinen E, Koskinen P. Transplant Proc. 1999;31(1-2):163-4.4.Blockade of PDGF receptor protein-tyrosine kinase activity effectively inhibits development of rat CMV infection enhanced experimental obliterative bronchiolitis. Tikkanen JM, Lemstrom K, Koskinen PK. J Heart Lung Transplant. 2001;20(2):1675.CD28/B7-2 pathway regulates the development of experimental obliterative bronchiolitis via promotion of TH1 cytokine expression. Tikkanen JM, Lemstrom K, Pulkkinen VP, Koskinen PK. J Heart Lung Transplant. 2001 Feb;20(2):252-2536.PDGF receptor inhibition prevents cardiac allograft arteriosclerosis in cholesterol-fed rabbits. Lemström K, Sihvola R, Tikkanen J, Aaltola E, Buchdunger E, Laitinen O, Koskinen P. Transplant Proc. 2001 Feb-Mar;33(1-2):3187.Endothelin-1 is biologically active in experimental rat obliterative bronchiolitis. Pulkkinen VP, Tikkanen JM, Lemström KB, Koskinen PK. Transplant Proc. 2001;33(1-2):4068.CD28-B7-2 but not CD28-B7-1 interaction is required for T cell costimulation in experimental obliterative bronchiolitis in the rat. Tikkanen JM, Lemström KB, Koskinen PK. Transplant Proc. 2001 Feb-Mar;33(1-2):5359.Cytomegalovirus infection-enhanced chronic rejection in the rat is prevented by antiviral prophylaxis. Tikkanen J, Kallio E, Pulkkinen V, Bruggeman C, Koskinen P, Lemström K. Transplant Proc. 2001 Feb-Mar;33(1-2):180110.Vascular endothelial growth factor plays a major role in development of experimental obliterative bronchiolitis. Krebs R, Hollmén ME, Tikkanen JM, Wu Y, Hicklin DJ, Koskinen PK, Lemström KB. Transplant Proc. 2006;38(10):3266-7.Reviews in peer-reviewed journals:1.Koskinen PK, Kallio EA, Tikkanen JM, Sihvola RK, Hayry PJ, Lemstrom KB. Cytomegalovirus infection and cardiac allograft vasculopathy. Transplant Infectious Disease. 1999;1(2):115-26.2.Kallio EA, Koskinen PK, Tikkanen JM, Lemstrom KB. Obliterative bronchiolitis: prevention. Transplant Proc 2001;33(1-2):1617-9.3.Lemström KB, Nykänen AI, Tikkanen JM, Krebs R, Sihvola RK, Kallio EA, Raisky O, Koskinen PK. Role of angiogeneic growth factors in transplant coronary artery disease. Ann Med 2004; 36: 184-193.4. Koskinen PK, Nykänen AI, Tikkanen JM, Sihvola RK, Krebs R, Lemström KB. Can we overcome chronic rejection? Duodecim 2004; 120: 1401-1409.5.Lemström K, Tikkanen J, Koskinen P, Häyry P. Effect of cytomegalovirus on cardiac allograft arteriosclerosis—indirect or direct? Am J Transplant 2005;5:421-2.6.Nykänen AI, Tikkanen JM, Krebs R, Keränen MA, Sihvola R, Sandelin H, Tuuminen R, Raisky O, Koskinen PK, Lemström KB. Angiogenic growth factors in cardiac allograft rejection. Transplantation 2006;15:82(1 Suppl):S22-4.Monograph:1.Tikkanen JM. Identification and inhibition of specific pathways leading to transplant obliterative bronchiolitis – an experimental approach in the rat. Helsinki 2003, University Printing Press. Academic Thesis.Articles in popular journals:1.Tikkanen JM. Keuhkosiirrännäisen krooninen hyljintäreaktio, voidaanko sitä estää? Hyvä Hengitys 2006:3:26-28.Other publications:1.Tikkanen JM. Yet Another Little Thing to Keep in Mind When Treating Lung Transplant Patients: Hyperammonemia. ISHLT Newsletter, March 2015. http://www.ishlt.org/ContentDocuments/2015Mar_Links.html#